2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for excessive pricing of patented medicines; and a range of court decisions addressed important issues. We considered over 60 patent decisions reported last year. In this article, we highlight statutory changes and a selection of interesting points addressed in the reported decisions. For a comprehensive review of Canadian pharmaceutical decisions and developments, please see the 2022 Highlights in Life Sciences IP and Regulatory Law in our Rx IP Update. Read more
Tuesday, January 17 2023 \ Published by JD Supra.
